Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Phase 3CompletedNCT03825380

Laboratoires Thea485 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

485

Conditions

Ocular Hypertension Glaucoma

Interventions

BimatoprostDRUG

Eyedrops

Lumigan®DRUG

Eyedrops

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent signed and dated. * Both eyes with diagnosed open-angle glaucoma or ocular hypertension Exclusion Criteria: * History of trauma, infection, clinically significant inflammation within the 3 previous months. * Uncontrolled diabetic patient. * Pregnancy or breast feeding.

Locations (1)

Hospital

Tallinn, Estonia

Outcomes

Primary Outcomes

Intra-Ocular Pressure

Change from Baseline to Week 12 in Intra Ocular Pressure in mmHg in the worse eye

Time frame: Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.